PF-04479745
Legal status | |
---|---|
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
ChEMBL | |
Chemical and physical data | |
Formula | C17H22N4 |
Molar mass | 282.391 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
PF-04479745 is a research ligand developed by Pfizer. It is related to lorcaserin, and acts as a potent and selective agonist for the 5-HT2C receptor, with lower affinity and antagonist action at the related 5-HT2A and 5-HT2B receptor subtypes.[1]
References
- ↑ Storer RI, Brennan PE, Brown AD, Bungay PJ, Conlon KM, Corbett MS, et al. (June 2014). "Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT2C) receptor agonists with exquisite functional selectivity over 5-HT2A and 5-HT2B receptors". Journal of Medicinal Chemistry. 57 (12): 5258–69. doi:10.1021/jm5003292. PMID 24878222.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.